Virtual substance use disorder companies sound alarm over PHE ending

The latest stories trending on MedCity News.

Editor's Pick

Top Story Virtual Substance Use Disorder Companies Sound Alarm Over PHE Ending The Covid-19 public health emergency waived a rule that required a practitioner to conduct an in-person medical exam before prescribing controlled substances via telemedicine. Once the public health emergency ends on May 11, those with substance use disorder could be greatly affected, experts are warning.

Featured News

J&J Drug for Rare Infant Blood Disorder Achieves Main Goal of Phase 2 Test A Johnson & Johnson drug acquired as part of a $6.5 billion deal has preliminary data showing it met the main goal of a mid-stage test in a rare blood disorder that can become fatal to fetuses. Full data from the trial will be presented at a future scientific meeting. ReKlame Health Expands Its Culturally Competent Behavioral Healthcare Model to 2 More States ReKlame Health launched in 2020 to provide affordable, culturally competent behavioral healthcare to Black and Brown communities in New York. On Monday, the startup announced it is now serving patients in two additional states — New Jersey and Florida. Unmind Acquires Frankie Health, Launches New Workplace Mental Health Product London-based Unmind offers a measurement tool that allows employees to gain insights into their own mental health. Its content library also provides access to exercises and self-guided courses. Dublin-based Frankie Health, meanwhile, connects employees to a global network of mental health practitioners. The combined organization's new product, Unmind Talk, joins the strengths of both companies. Nurse Labor Marketplace ShiftMed Snags $200M as Workforce Shortage Intensifies ShiftMed, an online marketplace for W-2 healthcare workers, recently raised $200 million in funding. The company's platform allows providers to post their open shifts in hopes they will be filled by local nurses. Gilead Sciences Drug Wins FDA Approval in Most Common Type of Breast Cancer Gilead Sciences drug Trodelvy is now approved for treating patients whose breast cancer is classified as HR positive and HER2 negative, expanding use of the drug to a much wider group of patients. In other regulatory approval news, use of Takeda Pharmaceutical's rare disease has expanded to younger children.

Resources

AI in Healthcare: Scratching the Surface Learn how AI is transforming the healthcare industry and the pitfalls that also exist with its early adoption.   Download Now

MedCity News • 611 Broadway • New York, NY unsubscribe